Why Inogen, Inc.’s (INGN) Stock Is Down 7.86%
As of Friday, August 07, Inogen, Inc.’s INGN share price has dipped by 7.86%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Commentary & Analysis
Why Inogen, Inc.’s (INGN) Stock Is Down 5.78%
As of Wednesday, August 05, Inogen, Inc.’s INGN share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Michael Rose
Why Inogen, Inc.’s (INGN) Stock Is Down 6.06%
As of Tuesday, June 30, Inogen, Inc.’s INGN share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Michael Rose
Why Inogen, Inc.’s (INGN) Stock Is Up 5.45%
As of Tuesday, June 09, Inogen, Inc.’s INGN share price has surged by 5.45%, which has investors questioning if this is right time to sell.Michael Rose
Why Inogen, Inc.’s (INGN) Stock Is Up 7.58%
As of Thursday, June 04, Inogen, Inc.’s INGN share price has surged by 7.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | INGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $136.1 | $372.5 | 24% |
|
| Shares Out (Mil) | 27.0 | 40.8 | 35% |
|
| Institutional Ownership | 96.1% | 83.3% | 69% |
|
| Float (Mil) | 23.1 | 35.1 | 31% |
|
| Beta | 1.60 | 0.87 | 85% |
|
| Avg Daily Volume (000s) | 290 | 287 | 50% |
|
| Price Change (52-week) |
(40.1%) | 63.4% | 21% |
|
| Growth | INGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.5% | 11.8% | 25% |
|
| Net Income (5yr) | (31.4%) | (5.7%) | 13% |
|
| EPS (5yr) | (26.1%) | 10.2% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (22.4%) | (15.5%) | 29% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.060) | ($0.280) | ($0.160) | |
| Month Ago EPS | $0.010 | ($0.280) | ($0.160) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.000 | ($0.370) | ($0.260) | |
| Year/Year Chg | (57.7%) | (67.4%) | (102.3%) | |
| Financials | INGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $354 | $123 | 37% |
|
| Net Income (TTM) (Mil) | ($25) | ($9) | 22% |
|
| EPS (TTM) | ($0.906) | ($0.400) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($3) | 28% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $1 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $23 | 30% |
|
| Enterprise Value (Q1) (Mil) | $70 | $376 | 18% |
|
| Valuation | INGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.78 | 2.79 | 15% |
|
| P/E | na | 25.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | INGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.5% | 58.7% | 55% |
|
| Net Margin | (6.9%) | (6.9%) | 23% |
|
| ROA | (8.2%) | (12.3%) | 26% |
|
| ROE | (13.1%) | (11.1%) | 26% |
|
| Liabilities to Assets | 38.8% | 46.6% | 29% |
|
| F-Score | 4 | 4 | 33% |
|
Inogen, Inc. did not pass any screens on 9/16/2026.
